The Emerging Revolution

By Edward Weck

Published: July, 2003

177 Pages, 12 Exhibits, 37 Companies Profiled, Published July 2003 

D&MD forecasts that the RNAi market will reach $185 million by 2008! 

Considered the greatest molecular biology innovation of the last decade or two, RNA Interference (RNAi) has become a recognized functional genomics research tool for mammalian gene knock-down studies, target discovery, and validation; and shows great therapeutic potential. The vast use for RNAi technology has motivated biotechnology and pharmaceutical companies, entrepreneurs, and venture capitalists to invest in the development and use of this technology. The market for RNAi is already expected to reach $38 million by the year's end.

D&MD's Commercial Opportunities in RNA Interference Market Analysis Report provides a thorough review of this promising technology. This Report will help you: 

Pinpoint the market potential of RNAi with an examination of projected market impact through 2008.

Discover the competitive advantage of RNAi over comparable technologies, such as antisense, ribozymes, peptide nucleic acids, and morpholinos from a comprehensive review of the capabilities and limitations of both.

Identify commercial opportunities for utilizing related technologies to fully implement RNAi, including protein and phenotype profiling, through an assessment of their abilities.

Look inside the key RNAi industry players developing siRNA therapeutics, using siRNA-mediated target validation, and specializing in siRNA and related reagents via detailed company profiles.

Learn about the patenting of RNAi with coverage of current patents and their holders.

Get an up-to-date technical review of RNAi through an evaluation of the latest developments, therapeutic breakthroughs, and uses of RNAi technologies. 

Publisher: Drug and Market Development 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/DMD_2003.html#a68